Drug Database
Back to search

Netherlands· NL-fbf641f98e64

Abacavir/Lamivudine/Zidovudine Mylan 300 mg/150 mg/300 mg filmomhulde tabletten

A zidovudine, lamivudine and abacavir product containing abacavirsulfaat + lamivudine 0-water + zidovudine, registered in Netherlands by Mylan Pharmaceuticals Limited. The same ATC class is registered in 10 of our 19 countries.

ATC J05AR04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAbacavir/Lamivudine/Zidovudine Mylan …ATCJ05AR04REGISTER NO.NL-fbf641f98e64PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about abacavirsulfaat + lamivudine 0-water + zidovudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Zidovudine, lamivudine and abacavir is registered in 10 of 19 countries.

Countries holding a registration under ATC J05AR04 (zidovudine, lamivudine and abacavir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search zidovudine, lamivudine and abacavir products by name

Zidovudine, lamivudine and abacavir · ATC J05AR04

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ABACAVIRSULFAAT + LAMIVUDINE 0-WATER + ZIDOVUDINE
Manufacturer
Mylan Pharmaceuticals Limited
Country
Netherlands (NL)
ATC code
J05AR04
ATC class
Zidovudine, lamivudine and abacavir
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    113105

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for zidovudine, lamivudine and abacavir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check zidovudine, lamivudine and abacavir against other medicinesHow interaction checks work

Zidovudine, lamivudine and abacavir · interactions on record

3 records

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Zidovudine, lamivudine and abacavir in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zidovudine, lamivudine and abacavir products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • France · Abacavir/Lamivudine/Zidovudine Viatris
  • Iceland · Trizivir
  • Italy · Abacavir/Lamivudina/Zidovudina Mylan
  • Liechtenstein · Trizivir
  • Norway · Trizivir

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea808de3-0df8-4064-91c8-ced091d299fa
GET /v1/drugs/ea808de3-0df8-4064-91c8-ced091d299fa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h113105_smpc.pdf",
  "strength": null,
  "atc_label": "Zidovudine, Lamivudine And Abacavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg113105",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ABACAVIRSULFAAT",
    "LAMIVUDINE 0-WATER",
    "ZIDOVUDINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h113105.pdf",
  "authorised_at": "2014/05/22",
  "procedure_number": "NL/H/2864/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "113105",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about zidovudine, lamivudine and abacavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console